مقالات پذیرفته شده در نهمین کنگره بین المللی زیست پزشکی
CRISPR-based nanobiosensors and gene delivery systems: Towards next-generation personalized medicine
CRISPR-based nanobiosensors and gene delivery systems: Towards next-generation personalized medicine
mahdieh kamali,1,*
1. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Introduction: The CRISPR Cas system has revolutionized genome editing and offers precise tools to address genetic diseases and cancers at their molecular roots. However, its full potential in clinical settings depends on overcoming challenges such as accurate detection and efficient delivery to target cells. Nanobiosensors, supported by CRISPR effectors such as Cas12 and Cas13, enable ultrasensitive detection of biomarkers such as circulating tumor DNA or viral RNA, while advanced gene delivery systems using nanomaterials such as lipids, polymers, and gold nanoparticles ensure safe and targeted delivery of CRISPR components. This review draws on recent early studies to explore how they pave the way for more personalized and effective therapies, transforming diagnosis and treatment in precision medicine.
Methods: The integration of CRISPR Cas systems with nanobiosensors and gene delivery technologies to advance personalized medicine. Studies were selected based on their originality, methodological rigor, and relevance to clinical applications, focusing on diagnostic sensitivity, therapeutic efficacy, and biocompatibility. The analysis explored two main areas: CRISPR based nanobiosensors for detecting disease biomarkers, and nanomaterial based systems for delivering CRISPR components to target cells. Experimental approaches were assessed across in vitro, ex vivo, and in vivo models, with outcomes analyzed for efficiency, specificity, and translational potential in precision medicine.
Results: CRISPR based biosensors have demonstrated remarkable accuracy in detecting pathogens and genetic mutations, often outperforming traditional methods with rapid, point-of-care capabilities. The integration of these technologies supports real-time monitoring and reduces risks, highlighting their versatility in personalized infectious disease and oncology diagnostics.
Conclusion: By combining the precision of CRISPR with the transduction and sensing power of nanotechnology, these systems hold promise for the next generation of personalized medicine, enabling early interventions and tailored therapies. Challenges such as scalability, long-term safety, and standardization remain, but continued innovation potentially enhanced by machine learning could accelerate clinical adoption. This review emphasizes the need for interdisciplinary efforts to fully harness these tools and ultimately improve patient outcomes in genetic and chronic diseases.